Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : M Ventures
Deal Size : $44.5 million
Deal Type : Series B Financing
UK biotech raises £35M to develop solid tumor drugs based on machine learning
Details : The company will fund its machine learning-driven discovery platform more comprehensive, to invest in its drug development for solid tumours creating antibody therapies.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 21, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : M Ventures
Deal Size : $44.5 million
Deal Type : Series B Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Innovate Biopharmaceuticals
Deal Size : $1.2 million
Deal Type : Funding
LabGenius Wins Government Innovation Grant to Support the Development of ML-driven Cancer Therapies
Details : LabGenius is pioneering the development of an ML-driven protein engineering platform. To date, EVA has co-optimised mono- and multi-specific single domain antibodies for biochemical and biofunctional properties, including stability, potency and selective...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 30, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Innovate Biopharmaceuticals
Deal Size : $1.2 million
Deal Type : Funding
Reset All
